Why Kidney Disease Innovation Is a Tale of Two Cities — and What It Would Take to Change That

Kidney disease drug development faces a stark divide between the rapid innovation occurring in rare disease therapeutics and the stagnant, investment-starved landscape of dialysis. While regulatory clarity and defined endpoints have catalyzed progress in rare conditions like IgA nephropathy, the dialysis sector remains hindered by a rigid, bundled payment structure that discourages the adoption of new, specialized treatments. John Butler, President and CEO of Akebia Therapeutics, highlights that current reimbursement models—which "peanut butter" costs across all dialysis sessions—effectively stifle innovation by failing to provide a sustainable path for new therapies. Legislative efforts like the Kidney Care Access Protection Act (K-CAPA) aim to bridge this gap by extending transitional payment adjustments and shifting toward a pay-per-use model. Ultimately, moving upstream to prevent disease progression and fostering more personalized, technology-driven care remain essential to transforming the future of renal medicine.